TACE and conformal radiotherapy . TACE alone for hepatocellular carcinoma: A randomised controlled trial.
Fiche publication
Date publication
avril 2023
Journal
JHEP reports : innovation in hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Féray C, Campion L, Mathurin P, Archambreaud I, Mirabel X, Bronowicki JP, Rio E, Perret C, Mineur L, Oberti F, Touchefeu Y, Gournay J, Regnault H, Edeline J, Rode A, Hillion P, Blanc JF, Khac EN, Azoulay D, Luciani A, Preglisasco AG, Faurel-Paul E, Auble H, Mornex F, Merle P
Lien Pubmed
Résumé
Transcatheter arterial chemoembolisation (TACE) is recommended for patients with hepatocellular carcinoma devoid of macrovascular invasion or extrahepatic spread but not eligible for curative therapies. We compared the efficacy and safety of the combination of a single TACE and external conformal radiotherapy (CRT) . classical TACE.
Mots clés
3-DCRT, three-dimensional conformal radiotherapy, AE, adverse event, ALBI, albumin–bilirubin, BCLC, Barcelona Clinic Liver Cancer, CRT, conformal radiotherapy, CT, computed tomography, CTV, clinical tumour volume, Conformal external radiotherapy, ECOG, Eastern Cooperative Oncology Group, HCC, hepatocellular carcinoma, HR, hazard ratio, Hepatocellular carcinoma, ITT, intention-to-treat, OS, overall survival, PFS, progression-free survival, PS, propensity score, RILD, radio-induced liver disease, SBRT, stereotaxic body radiation therapy, TACE, transcatheter arterial chemoembolisation, TTP, time to tumour progression, mRECIST, modified Response Evaluation Criteria in Solid Tumour
Référence
JHEP Rep. 2023 04;5(4):100689